| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11899-011-0104-Z |
| P698 | PubMed publication ID | 22105489 |
| P2093 | author name string | Jan A Burger | |
| P2860 | cites work | ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL) | Q81583965 |
| Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14+ cells from peripheral blood | Q83225209 | ||
| Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling | Q83587583 | ||
| ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain | Q24294340 | ||
| Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk | Q24303475 | ||
| Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia | Q24322068 | ||
| Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia | Q24599100 | ||
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia | Q24675399 | ||
| Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk | Q28140552 | ||
| PI3K in lymphocyte development, differentiation and activation | Q28187880 | ||
| A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation | Q28202234 | ||
| Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice | Q28215433 | ||
| Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 | Q28216101 | ||
| Chronic lymphocytic leukemia | Q28236621 | ||
| Syk tyrosine kinase required for mouse viability and B-cell development | Q28586985 | ||
| Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia | Q30195143 | ||
| Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta(2) integrin-mediated rolling on intercellular adhesion molecule-1. | Q30440643 | ||
| Intrinsic properties of immunoglobulin IgG1 isotype-switched B cell receptors promote microclustering and the initiation of signaling | Q30495504 | ||
| Comprehensive assessment of chemokine expression profiles by flow cytometry | Q33685627 | ||
| In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells | Q33830733 | ||
| The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms | Q33922899 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| PI3K/p110{delta} is a novel therapeutic target in multiple myeloma | Q34124937 | ||
| Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target | Q34162571 | ||
| Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 | ||
| Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas | Q34275448 | ||
| Antigen receptors on B lymphocytes | Q34420640 | ||
| Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. | Q34443608 | ||
| The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia | Q34542102 | ||
| R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation | Q34562439 | ||
| B cell antigen receptor signaling: roles in cell development and disease. | Q34662623 | ||
| B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor | Q35077432 | ||
| B-cell antigen-receptor signalling in lymphocyte development | Q35591032 | ||
| Chronic lymphocytic leukemia: revelations from the B-cell receptor. | Q35667038 | ||
| CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia | Q35868355 | ||
| Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement | Q36368492 | ||
| Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia | Q36399593 | ||
| ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia | Q36478480 | ||
| B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. | Q37028635 | ||
| Primary B cell immunodeficiencies: comparisons and contrasts | Q37419369 | ||
| The microenvironment in mature B-cell malignancies: a target for new treatment strategies | Q37563816 | ||
| CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability | Q39642145 | ||
| The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia | Q39722770 | ||
| Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. | Q39935053 | ||
| Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells | Q39992623 | ||
| Oncogenic CARD11 mutations in human diffuse large B cell lymphoma | Q40005246 | ||
| The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells | Q40069478 | ||
| Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. | Q40291337 | ||
| Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma | Q40330626 | ||
| Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. | Q40916348 | ||
| Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. | Q40960823 | ||
| Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib | Q41763842 | ||
| PI3 kinase signals BCR-dependent mature B cell survival | Q41886641 | ||
| High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation | Q42184742 | ||
| Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes | Q42941748 | ||
| The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. | Q42945085 | ||
| High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease | Q43127229 | ||
| Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia | Q44189657 | ||
| Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. | Q44189712 | ||
| CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival | Q44276636 | ||
| Expression of Bruton's tyrosine kinase protein within the B cell lineage | Q44760438 | ||
| ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia | Q44859885 | ||
| ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia | Q46112511 | ||
| Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial | Q46271720 | ||
| Role of CCL3 protein (monocyte inflammatory protein-1 alpha) in lymphoid malignancy. | Q46965943 | ||
| Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins | Q47290633 | ||
| The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. | Q47316124 | ||
| Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. | Q53646132 | ||
| Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. | Q54648964 | ||
| BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. | Q55034216 | ||
| ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. | Q55036524 | ||
| Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and Homing | Q58324020 | ||
| ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile | Q73023141 | ||
| Survival of leukemic B cells promoted by engagement of the antigen receptor | Q77136413 | ||
| Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma | Q79188284 | ||
| CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment | Q80837099 | ||
| P433 | issue | 1 | |
| P921 | main subject | leukemia | Q29496 |
| lymphocyte | Q715347 | ||
| P304 | page(s) | 26-33 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Current hematologic malignancy reports | Q26842233 |
| P1476 | title | Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia | |
| P478 | volume | 7 |
| Q36936456 | Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies |
| Q36686403 | Associations between dietary patterns and gene expression profiles of healthy men and women: a cross-sectional study |
| Q34398579 | B-cell receptor signaling as a driver of lymphoma development and evolution |
| Q38101590 | BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies |
| Q38074145 | Clonal expansion in B-CLL: fungal drivers or self-service? |
| Q47424531 | Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia |
| Q51232163 | Expression of Bruton's tyrosine kinase in B-cell neoplasms evaluated by flow cytometry. |
| Q39048554 | Functional proteomic insights in B-cell chronic lymphocytic leukemia. |
| Q38056832 | GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia |
| Q36602853 | MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies |
| Q38984569 | Modeling the chronic lymphocytic leukemia microenvironment in vitro |
| Q86483631 | Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis |
| Q33978930 | Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion |
| Q37422201 | Overview of recent developments in chronic lymphocytic leukemia |
| Q34342465 | PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q38872127 | RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia |
| Q42320922 | Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies |
| Q38025162 | Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. |
| Q35583403 | The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. |
| Q39180275 | The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia |
| Q35489417 | The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia |
| Q35583972 | VDJSeq-Solver: in silico V(D)J recombination detection tool |
| Q36647928 | p110δ PI3 kinase pathway: emerging roles in cancer |
Search more.